




A



B





(A) or pooled 30mers (B) were used. DMSO negative control was subtracted from all values. NT, not tested, NA, not applicable. (C) Distribution of vaccine-specific CD8⁺ and CD4⁺ T-cells upon stimulation with 9-mer peptides and 30-mer peptides measured by *ex vivo* intracellular cytokine staining (ICS) assay. Average distribution of vaccine peptide-specific polyfunctional CD8⁺ (D) and CD4⁺ (E) T-cell Responses detected before vaccination (PRE), after 1 (*n*=9), 2 (*n*=4), or 3 (*n*=4) vaccine doses as measured by *ex vivo* ICS assay. (F) Representative (*ex vivo*) IFN- γ – CD8 or CD4 ICS dot plots (one of three replicates) for patient 01-0005 before vaccination (PRE), and after 1 dose (week 3+6 pooled), after 2 doses (week 19), and after 3 doses (week 32) measured with pools of 9mers or 30mers and DMSO negative control.